TN-1321

Next-level Sensitivity for the Quantification of Warfarin and Furosemide in Human Plasma

Ian Moore¹, Rahul Baghla², and Bryan Tackett, PhD³ ¹AB Sciex LP, 71 Four Valley Drive, Concord, Ontario L4K 4V8, Canada ²AB Sciex, 1201 Radio Road, Redwood City, CA 94065, USA ³Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA

Introduction

This technical note demonstrates the sensitive quantification of small molecule pharmaceutical compounds extracted from human plasma using minimal sample preparation and negative ion mode-based analysis. Lower limits of quantification (LLOQs) of 3.13 pg/mL and 25 pg/mL were achieved for Warfarin and Furosemide, respectively. Quantitative performance of the assay highlighted outstanding precision, accuracy, and linearity. Enhanced assay sensitivity was achieved through the application of a high-end triple quadrupole mass spectrometer to meet the demands of routine bioanalysis in complex matrices.

Demand for improved sensitivity in bioanalytical assays continues to increase as drug discovery and development programs focus on more efficacious, lower dosage compounds and as throughput demands drive the simplification of sample extraction and LC and MS methods. In many cases, the use of a more sensitive mass spectrometer is the easiest way to meet these needs. Having a system that offers technological improvements that deliver sensitivity gains across the mass range and in both polarities offers the bioanalytical scientist maximum flexibility to address the challenges outlined above. Here, Warfarin and Furosemide were extracted from human plasma and quantified using a negative ion mode approach on the SCIEX 7500 system (**Figure 1**). The improved front-end technology of the system enabled greater ion generation, capture and transmission to improve sensitivity for routine bioanalysis.

Sample Preparation

Warfarin and Furosemide were spiked into 100 μL aliquots of human plasma at concentrations ranging from 3.13 to 100,000 pg/mL. Samples were extracted using protein precipitation with 300 μL Acetonitrile. The samples were then vortexed and centrifuged at 10,000 rpm for 25 minutes. The supernatant was collected for analysis.



LC Conditions

Column:	Kinetex™ 1.7 μm C18		
Dimensions:	50 x 2.1 mm		
Part No.:	00B-4475-AN		
Mobile Phase:	A: 0.01 % Formic Acid in Water		
	B: 0.01 % Formic Acid in Acetonitrile		
Gradient:	Time (min) %B		
	0	15	
	0.25	15	
	3 50		
	3.1 95		
	4 95		
	4.1 15		
	5	15	
Flow Rate:	0.6 mL/min		
Injection Volume:	1 μL		
Temperature:	Ambient		
LC System:	SCIEX [®] ExionLC [™]		
Detection:	MS/MS		
Detector:	SCIEX Triple Quad™ 7500		

MS/MS Conditions

Polarity:	Negative
Source Temperature:	650 °C
GS1:	60 psi
GS2:	70 psi
CUR:	40 psi
CAD:	10
IS:	1700 V

MS/MS Transitions and Parameters

Analyte	Q1 (m/z)	Q3 (m/z)	EP (V)	CE (V)	CXP (V)
Warfarin	307.1	250.1	-10	-31	-9
Furosemide	329	77.9	-10	-40	-9

PHEN-RUO-00185

Results and Discussion

Calibration curves were acquired across the concentration range of 3.13 to 100,000 pg/mL. Each concentration was analyzed in triplicate to assess method reproducibility. Strong linearity was observed across the concentration ranges analyzed, as demonstrated in **Figures 2** and **3** for Warfarin and Furosemide, respectively. **Table 1** summarizes the quantification results, including accuracy and precision. Excellent %CVs were achieved across all concentration levels with no interference in the blank human plasma samples for Warfarin and Furosemide. Using a generic sample preparation technique for the analysis of 100 μ L of human plasma and a total run time of 5 minutes, the method provided LLOQs of 3.13 pg/mL and 25 pg/mL for Warfarin and Furosemide, respectively (**Figures 4** and **5**).

Figure 1. Extracted Ion Chromatograms (XICs) Representing the Matrix Blank and LLOQs of Warfarin and Furosemide Extracted from Human Plasma.



Figure 2. The Calibration Curve for Quantification of Warfarin in Human Plasma.







TN-1321

	Warfarin		Furosemide	
Concentration (fmol/μL)	Accuracy (%)	CV (%)	Accuracy (%)	CV (%)
3.13	100	9.2	N/A	N/A
6.25	94.5	4.1	N/A	N/A
12.5	103	1.4	N/A	N/A
25.0	106	2.6	104	15.3
62.5	115	1.7	91.6	10.2
250	103	0.8	88.5	1.6
1000	100	1.5	102	1.3
4000	97.1	1.4	104	1.2
20,000	89.1	1.3	99.4	0.1
40,000	91.2	0.9	107	3.1
80,000	N/A	N/A	104	1.8
100,000	N/A	N/A	99.2	4.5

Table 1. Quantification Summary for Warfarin and Furosemide.

Figure 4. XICs Demostrating Warfarin Extraction from Human Plasma. a) Matrix Blank, and Warfarin present at b) 3.13 pg/mL, c) 6.25 pg/mL, d) 12.5 pg/mL, and e) 25 pg/mL.



Figure 5. XICs Demostrating Furosemide Extraction from Human Plasma. a) Matrix Blank, and Furosemide present at b) 25 pg/mL, c) 62.5 pg/mL, d) 250 pg/mL, and e) 1000 pg/mL.



?



Conclusions

Low-pg/mL level LLOQs were reached for Warfarin and Furosemide extracted from human plasma using minimal sample preparation. A highly sensitive assay for the quantification of small molecule pharmaceutical compounds requiring negative ion mode-based analysis was demonstrated on the SCIEX® 7500 system. The method demonstrated excellent accuracy, precision, and linearity at all concentration levels. A single platform for streamlined data acquisition, processing, and management with SCIEX OS software was presented. Overall, the SCIEX 7500 system enables pharmaceutical researchers the maximum flexibility to explore lower dosage, higher efficacy compounds, and improve the efficiency of bioanalysis.

Kinetex[™] Ordering Information

SecurityGuard™ 1.7 μm Minibore Columns (mm) ULTRA Cartridges [‡]					
	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
EVO C18		<u>00B-4726-AN</u>	00D-4726-AN	<u>00F-4726-AN</u>	<u>AJ0-9298</u>
Biphenyl	<u>00A-4628-AN</u>	00B-4628-AN	00D-4628-AN	00F-4628-AN	<u>AJ0-9209</u>
XB-C18	<u>00A-4498-AN</u>	<u>00B-4498-AN</u>	00D-4498-AN	00F-4498-AN	<u>AJ0-8782</u>
C18	<u>00A-4475-AN</u>	<u>00B-4475-AN</u>	00D-4475-AN	<u>00F-4475-AN</u>	<u>AJ0-8782</u>
C8	<u>00A-4499-AN</u>	00B-4499-AN	00D-4499-AN	00F-4499-AN	<u>AJ0-8784</u>
HILIC	<u>00A-4474-AN</u>	<u>00B-4474-AN</u>	00D-4474-AN	—	<u>AJ0-8786</u>
Phenyl-Hexyl		00B-4500-AN	00D-4500-AN	00F-4500-AN	<u>AJ0-8788</u>
F5	-	<u>00B-4722-AN</u>	00D-4722-AN	<u>00F-4722-AN</u>	<u>AJ0-9322</u>

for 2.1 mm ID

*SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000



Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on <u>www.phenomenex.com</u>, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal <u>www.phenomenex.com/Chat</u>.

India

Indonesia

Ireland

Japan t: +81 (0) 120-149-262

Mexico

t: +62 21 5019 9707

t: +353 (0)1 247 5405

Italy t: +39 051 6327511

Luxembourg t: +31 (0)30-2418700

t: 01-800-844-5226

The Netherlands

t: +31 (0)30-2418700

New Zealand

Norway t: +47 810 02 005

t: +48 22 104 21 72

Poland

t: +64 (0)9-4780951

t: +91 (0)40-3012 2400

indiainfo@phenomenex.com

indoinfo@phenomenex.com

eireinfo@phenomenex.com

italiainfo@phenomenex.com

jpinfo@phenomenex.com

nlinfo@phenomenex.com

nlinfo@phenomenex.com

nzinfo@phenomenex.com

nordicinfo@phenomenex.com

pl-info@phenomenex.com

tecnicomx@phenomenex.com

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belgium t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

Czech Republic t: +420 272 017 077 cz-info@phenomenex.com

Denmark t: +45 4824 8048 nordicinfo@phenomenex.com

Finland t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

Hong Kong t: +852 6012 8162 hkinfo@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right. www.phenomenex.com/behappy

Portugal t: +351 221 450 488 ptinfo@phenomenex.com

> Singapore t: +65 6559 4364 sginfo@phenomenex.com

Slovakia t: +420 272 017 077 sk-info@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

Sweden t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

Thailand t: +66 (0) 2 566 0287 thaiinfo@phenomenex.com

United Kingdom t: +44 (0)1625-501367 ukinfo@phenomenex.com

USA t: +1 (310) 212-0555 www.phenomenex.com/chat

 All other countries/regions Corporate Office USA
t: +1 (310) 212-0555
www.phenomenex.com/chat

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at <u>www.phenomenex.com/phx-terms-and-conditions-of-sale</u>. Trademarks

Kinetex, SecurityGuard, and BE-HAPPY are trademarks of Phenomenex. SCIEX is a registered trademark and Triple Quad and ExionLC are trademarks of AB SCIEX Pte. Ltd. Disclaimer

Comparative separations may not be representative of all applications.

SecurityGuard is patented by Phenomenex. U.S. Patent No. 6,162,362

CAUTION: this patent only applies to the analytical-sized guard cartridge holder, and does not apply to SemiPrep, PREP, or ULTRA holders, or to any cartridges.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2022 Phenomenex, Inc. All rights reserved.

Page 5 of 5

